CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

CureMatch Presents PreciGENE Performance Results at AACR Annual Meeting

CureMatch Presents PreciGENE Performance Results at AACR Annual Meeting
ResearchValidation

SAN DIEGO, CA – April 13, 2018 – CureMatch, Inc. announces the presentation of new data showcasing advances in Precision Oncology at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18.

The poster, titled ‘Understanding tumor biology complexity in the advanced cancer setting: PreciGENE® platform predictions correlate with exceptional responses to cancer treatment’ will be presented by Amelie Boichard, Pharm.D, Ph.D and Stephane Richard, Ph.D, on Monday, April 16, 1:00PM CDT, during the ‘New Software for Data Analysis’ session.

This study highlights the possible benefits of an evidence-based selection of personalized therapy options in terms of patient response, and validates the data mining methods and optimized algorithms used by the CureMatch PreciGENE® therapeutic decision-support system.

The authors performed a retrospective analysis on published data of 70 cancer patients whose tumors were profiled by DNA sequencing or other molecular assay(s) and who received a total of 202 treatment lines. These patients presented an exceptional treatment response to at least one drug regimen. The CureMatch platform ranked all treatment regimens (both successful and unsuccessful) using the PreciGENE Score, reflecting the degree to which a therapy or combination of therapies matches a patient’s biomarker profile. The results revealed that the matching scores obtained for regimens that led to a positive outcome were significantly higher than those obtained for regimens that failed. The PreciGENE decision-support system predicted correctly the response to treatment in almost 80% of the cases (161 out of 202 regimens).

“This study demonstrates that the unique molecular profile presented by a patient’s tumor may explain the variability of responses observed after cancer therapy,” stated Razelle Kurzrock, M.D., co-founder of CureMatch and Director of the Center for Personalized Cancer Therapy at UC San Diego. “In the near future, comprehensive analysis of cancer fingerprints will become an important step in modern clinical practice. Physicians will be able to guide clinical decisions based on better forecasted patient outcomes, which in turn will ultimately lead to a significant improvement of the healthcare system.”

“Offering oncologists actionable analysis to best treat individual cancer patients is at the center of everything we do at CureMatch,” stated Stephane Richard, Ph.D., President and CEO of CureMatch. “We believe the future of cancer care requires truly personalized treatments, and our collective goal is to provide optimized treatment options to advance the standards of clinical cancer practice.”

The PreciGENE® therapeutic decision-support system is the result of a sponsored collaboration between CureMatch Inc., UC San Diego and the San Diego Super-Computer Center. The platform has been optimized using molecular profiles clinically reviewed during weekly pluri-disciplinary meetings (tumor boards) at the UCSD Center for Personalized Cancer Therapy, and is currently tested in several prospective and retrospective validation studies.

The abstract details for this retrospective study can be viewed here, and if you are attending the AACR 2018 conference, please connect with us to discuss the future of precision oncology.

Cancer Research: 78 (13)

UPDATE: AACR published the CureMatch abstract in their Journal, Cancer Research. You may view the published abstract online here and the poster is shown below (click it to view an enlarged PDF version).


AACR-Retrospective-Study-Poster-04-10-2018


About AACR Cancer Research Journal
The American Association for Cancer Research (AACR) journal Cancer Research publishes original studies, reviews, and opinion pieces offering significance and broad impact to a diverse audience. Cancer Research seeks manuscripts that offer pathobiological and translational impact to inform the personal, clinical, and societal problems posed by cancer. The main scope of the journal is captured in its primary subsections: Genome and Epigenome, Metabolism and Chemical Biology, Molecular Cell Biology, Tumor Biology and Immunology, Translational Science, Convergence and Technologies, and Population and Prevention Science.

###

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE® reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, molecular and cell biology.

The CureMatch intelligent computing system assists oncologists with the daunting task of selecting the most promising combinations of anticancer drugs for each patient. Utilizing proprietary algorithms to analyze over 4.5 million combinations of commonly used as well as newly approved cancer treatments found in massive pharmacological and clinical databases, CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations and improve the precision of cancer treatment recommendations. Download a PreciGENE Sample Analysis.

Media Contact
Name: Larissa Anderson
Company: CureMatch
Phone: 858-859-2873
Email: press@curematch.com

 

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data